8STN Stock Overview Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Sorrento Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Sorrento Therapeutics Historical stock prices Current Share Price US$0.30 52 Week High US$2.79 52 Week Low US$0.13 Beta 2.12 1 Month Change 0% 3 Month Change 19.20% 1 Year Change -80.28% 3 Year Change -91.94% 5 Year Change -95.22% Change since IPO -94.92%
Recent News & Updates Final DIP Financing Approved for Sorrento Therapeutics, Inc. Mar 14
Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc. Mar 13
Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors Oct 28
Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso Sep 13
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients Sep 08 Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million. Aug 09
See more updates Final DIP Financing Approved for Sorrento Therapeutics, Inc. Mar 14
Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc. Mar 13
Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors Oct 28
Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso Sep 13
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients Sep 08 Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million. Aug 09
Sorrento Therapeutics, Inc. announced delayed 10-Q filing Aug 08
Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R Mzl) Jul 06
Sorrento Therapeutics, Inc. Announces Full Enrollment of Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), Second Generation Oral Mpro Inhibitor, as Standalone Treatment for COVID-19 Jun 28 Sorrento Therapeutics, Inc. announced delayed 10-Q filing May 10
Sorrento Therapeutics, Inc.(NasdaqCM:SRNE) dropped from S&P Biotechnology Select Industry Index Sorrento Therapeutics Received Written Notice from the Staff of The Nasdaq Stock Market LLC
Sorrento Therapeutics, Inc., Annual General Meeting, Apr 06, 2023 Feb 05
Sorrento Therapeutics, Inc. Releases Unblinded Phase 1B Study Data of Its Oral Main Viral Protease Inhibitor, OVYDSO™ (STI-1558) in Covid Patients Jan 10
Sorrento Therapeutics Receives FDA Clearance to Initiate Clinical Trials with A Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus Dec 08
Sorrento Therapeutics, Inc. Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented At Asian Congress of the European Society for Medical Oncology (Esmo) Dec 06
Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from A Phase IB Study in China with STI-1558 Nov 30
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released: US$0.20 loss per share (vs US$0.40 loss in 3Q 2021) Nov 10
Less than half of directors are independent Nov 09
Sorrento Therapeutics, Inc., Annual General Meeting, Dec 15, 2022 Nov 02
Sorrento Therapeutics, Inc. Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with Sti-1558, an Oral Mpro Inhibitor as A Standalone Oral Treatment and Prevention of Covid-19 Without the Need for A Ritonavir Booster Oct 18
Sorrento Therapeutics, Inc. Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients Sep 27
Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures At 50% of the Standard Dose for Patients (7 of 7) with an Inadequate Response to Subcutaneous Injections Sep 16
Sorrento Therapeutics, Inc. Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib for the Treatment of Advanced Non-Small Cell Lung Cancer Aug 24
Sorrento Therapeutics, Inc. Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients Aug 20 Sorrento Therapeutics, Inc. announced delayed 10-Q filing Aug 10
Sorrento Therapeutics, Inc. Announces the Completion of the SAD Portion of the Phase 1 Study of Its Oral Main Viral Protease (Mpro) Inhibitor, the STI-1558 Aug 04
Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19 Jul 20
Sorrento Therapeutics, Inc. Announces First Subject Dosed in A Phase I Clinical Study of Sti-1558, an Oral Mpro Inhibitor as A Standalone Treatment and Prevention of Covid-19 Without Co-Administration of Ritonavir Booster Jun 04
Less than half of directors are independent Jun 01
Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors May 19
Sorrento Therapeutics, Inc. Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial) May 18
Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern May 03
Sorrento Therapeutics, Inc. Announces That It Has Received Clearance from the FDA for Its Investigational New Drug Application for Intravenous (Iv) Sti-9167 Apr 26
Sorrento Therapeutics Announces the Appointment of Laura Hamill to Its Board of Directors Apr 13 Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients with Severe Pneumonia Due to Covid-19 Apr 01
Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infections When Given 24 Hours Prior to Virus Exposure
Sorrento Therapeutics, Inc. announced delayed annual 10-K filing Mar 03
Sorrento Therapeutics, Inc Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses Feb 24
Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) acquired an unknown majority stake in Zhengzhou Fortune Bioscience Co., Ltd.. Feb 18
Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) completed the acquisition of Virex Health, Inc. Feb 02
Sorrento Announces its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralizes Omicron Jan 30
Sorrento Therapeutics, Inc. Announces Covishield (STI-9167), A Broad-Spectrum Neutralizing Antibody, Potently Neutralizes Omicron and Omicron (+R346K) Variants of Sars-Cov-2 Jan 22
Sorrento Therapeutics, Inc. Announces Completion of Enrollment in US Phase 2 Clinical Trial for Covi-Drops and Achievement of Interim Analysis Threshold in the UK Jan 20
Brazilian Health Regulatory Agency Authorizes Sorrento Therapeutics, Inc.'s Phase 2 Clinical Trial of COVI-MSC in COVID-19 Patients With Persistent Pulmonary Compromise After Recovery (Long-Hauler) Jan 19
Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors Dec 21
Sorrento Therapeutics, Inc. Begins Enrollment in Phase 2 Trial of Resiniferatoxin for the Treatment of Pain Due to Knee Osteoarthritis (OA) Dec 08
Sorrento Announces Publication of Series of Novel Sars-Cov-2 Main Protease (Mpro) Inhibitors for Potential Treatment of Covid-19 Patients Infected with Sars-Cov-2 Variants of Concern, Including Omicron Dec 07
Insufficient new directors Dec 06
Third quarter 2021 earnings released: US$0.40 loss per share (vs US$0.33 loss in 3Q 2020) Nov 07
Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globally Leading Rapid Antigen Test Sep 21
Sorrento Therapeutics, Inc. Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients Sep 03
Sorrento Therapeutics, Inc. Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device Aug 27
Sorrento Therapeutics, Inc. Publishes Positive Initial Results of Sofusa® Lymphatic Drug Delivery System in A Phase 1B Rheumatoid Arthritis Study Using Enbrel Aug 24
Sorrento Announces its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern Aug 21
Sorrento Therapeutics, Inc. Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program Aug 12
No longer forecast to breakeven Aug 10
Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.36 loss in 2Q 2020) Aug 08
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma Aug 04
Sorrento Therapeutics, Inc. Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS Jul 23 Sorrento Therapeutics, Inc.(NasdaqCM:SRNE) dropped from Russell 3000E Index
Sorrento Therapeutics, Inc. Receives Emergency Use Authorization Approval and Import License from COFEPRIS for COVI-STIX and Plans Product Launch with Initial Shipments in July Jun 25
Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of Third Quarter of 2021 Jun 23
Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting Jun 12
Sorrento Announces Positive Results from Its License Partner, Kelun, on A Phase I Study of Safety and Pharmacokinetics of A166, A Novel Her2 ADC for Advanced Her2 Positive Breast Cancers Jun 05 Sorrento Therapeutics, Inc. (NasdaqCM:SRNE) completed the acquisition of ACEA Therapeutics, Inc. for approximately $550 million. Brazilian Health Regulatory Agency Authorizes Sorrento Therapeutics, Inc.'s Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients with Acute Respiratory Distress Syndrome
First quarter 2021 earnings released: EPS US$0.009 (vs US$0.36 loss in 1Q 2020) May 07
Sorrento Therapeutics, Inc. Receives FDA Clearance to Proceed with Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma Apr 28
Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate Mar 19
Sorrento and Mount Sinai Health System Enter into License Agreement Mar 11 Shareholder Returns 8STN DE Biotechs DE Market 7D 0% 3.1% 0.5% 1Y -80.3% -13.8% 7.2%
See full shareholder returns
Return vs Market: 8STN underperformed the German Market which returned 5.9% over the past year.
Price Volatility Is 8STN's price volatile compared to industry and market? 8STN volatility 8STN Average Weekly Movement n/a Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 8STN's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 8STN's volatility change over the past year.
About the Company Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.
Show more Sorrento Therapeutics, Inc. Fundamentals Summary How do Sorrento Therapeutics's earnings and revenue compare to its market cap? 8STN fundamental statistics Market cap €154.45m Earnings (TTM ) -€626.04m Revenue (TTM ) €56.58m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 8STN income statement (TTM ) Revenue US$60.71m Cost of Revenue US$233.93m Gross Profit -US$173.23m Other Expenses US$498.42m Earnings -US$671.64m
Last Reported Earnings
Mar 31, 2023
Earnings per share (EPS) -1.24 Gross Margin -285.36% Net Profit Margin -1,106.41% Debt/Equity Ratio -55.7%
How did 8STN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/05/31 06:45 End of Day Share Price 2023/03/03 00:00 Earnings 2023/03/31 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sorrento Therapeutics, Inc. is covered by 15 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raghuram Selvaraju Aegis Capital Corporation James Molloy Alliance Global Partners Difei Yang Brean Capital
Show 12 more analysts 
